The Best Small-Cap Stocks to Buy Now
Biotech, real estate and software dominate the list of Wall Street's best small-cap stocks to buy.


The final quarter of 2025 and first quarter of the new year could be much more favorable for stockpickers looking for the best small-cap stocks to buy.
That might sound counterintuitive after the way small caps have underperformed during the current bull market. After all, small caps as an asset class have been a dud. They've struggled to keep up as mega-cap stocks pushed the broader market to record highs.
To recap: the broader S&P 500 is up more than 80% since the bull market's onset three years ago. The tech-heavy Nasdaq Composite more than doubled over the same span. Hurt partly by its price-weighted construction, the blue-chip Dow Jones Industrial Average gained just 55%.
From just $107.88 $24.99 for Kiplinger Personal Finance
Be a smarter, better informed investor.

Sign up for Kiplinger’s Free Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
Select Magnificent 7 stocks such as Nvidia (NVDA) and Microsoft (MSFT) have been fueling much of the market's gains. And so small caps – which tend to be more sensitive to the economic cycle, tariffs and interest rates – are lagging badly.
Indeed, the small-cap benchmark Russell 2000 Index is up just 41% over the past three years.
If there is a sliver of a silver lining to the Russell 2000's chronic underperformance, it's that small cap valuations look dirt cheap.
"The broadening of profits growth is finally extending into small caps," notes Jill Carey Hall, an equity and quant strategist at BofA Securities. "Small caps continue to trade at about a 30% historical discount to large caps, implying likelihood of outperformance over the long-term. We remain constructive on small caps for now."
And with the Federal Reserve expected to enact several cuts to the federal funds rate in the coming quarters, small caps should have at least one catalyst behind them.
Our methodology for finding the best small-caps stocks to buy
In order to find the best small-cap stocks to buy now, we started by screening the Russell 2000 for Wall Street analysts' top-rated names.
Here's how the process works: S&P Global Market Intelligence surveys analysts' stock ratings and scores them on a five-point scale, where 1.0 equals Strong Buy and 5.0 means Strong Sell.
Any score of 2.5 or lower means that analysts, on average, rate the stock a Buy. The closer the score gets to 1.0, the stronger the Buy call.
In other words, lower scores are better than higher scores.
We further limited ourselves to stocks with at least 12 Strong Buy recommendations to ensure adequate analyst coverage and sample size. Lastly, we dug into research, fundamental factors, valuation, analysts' estimates and other data to find the best stocks to buy.
Our screen of the Street's top small-cap stocks served up a list dominated by the health care sector, mostly pharmaceutical and biotechnology companies.
That's to be expected, and investors should always do their own due diligence when considering, say, a clinical-stage biotech firm, which is essentially a speculative investment.
In other cases, some of these names – a gaming stock and real estate investment trust (REIT), for instance – might just surprise you.
And with that, have a look at the table below to see Wall Street's best small-cap stocks to buy now.
Company (Ticker) | Analysts' consensus recommendation score | Subsector | Analysts' consensus recommendation |
---|---|---|---|
Spyre Therapeutics (SYRE) | 1.14 | Biotechnology | Strong Buy |
Denali Therapeutics (DNLI) | 1.16 | Biotechnology | Strong Buy |
Waystar Holding (WAY) | 1.19 | Health Care Technology | Strong Buy |
Xenon Pharmaceuticals (XENE) | 1.21 | Biotechnology | Strong Buy |
Genius Sports (GENI) | 1.22 | Casinos & Gaming | Strong Buy |
Janux Therapeutics (JANX) | 1.22 | Biotechnology | Strong Buy |
Axsome Therapeutics (AXSM) | 1.25 | Pharmaceuticals | Strong Buy |
Wave Life Sciences (WVE) | 1.27 | Pharmaceuticals | Strong Buy |
Kymera Therapeutics (KYMR) | 1.27 | Biotechnology | Strong Buy |
Riot Platforms (RIOT) | 1.28 | Application Software | Strong Buy |
Avidity Biosciences (RNA) | 1.28 | Biotechnology | Strong Buy |
Braze (BRZE) | 1.30 | Application Software | Strong Buy |
Biohaven (BHVN) | 1.33 | Biotechnology | Strong Buy |
Guardant Health (GH) | 1.35 | Health Care Services | Strong Buy |
BridgeBio Pharma (BBIO) | 1.37 | Biotechnology | Strong Buy |
Essential Properties Realty Trust (EPRT) | 1.37 | Diversified REITs | Strong Buy |
Arcellx (ACLX) | 1.39 | Biotechnology | Strong Buy |
Privia Health Group (PRVA) | 1.40 | Health Care Services | Strong Buy |
IDEAYA Biosciences (IDYA) | 1.42 | Biotechnology | Strong Buy |
NetSTREIT (NTST) | 1.50 | Retail REITs | Strong Buy |
Related content
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more. Delivered daily. Enter your email in the box and click Sign Me Up.

Dan Burrows is Kiplinger's senior investing writer, having joined the publication full time in 2016.
A long-time financial journalist, Dan is a veteran of MarketWatch, CBS MoneyWatch, SmartMoney, InvestorPlace, DailyFinance and other tier 1 national publications. He has written for The Wall Street Journal, Bloomberg and Consumer Reports and his stories have appeared in the New York Daily News, the San Jose Mercury News and Investor's Business Daily, among many other outlets. As a senior writer at AOL's DailyFinance, Dan reported market news from the floor of the New York Stock Exchange.
Once upon a time – before his days as a financial reporter and assistant financial editor at legendary fashion trade paper Women's Wear Daily – Dan worked for Spy magazine, scribbled away at Time Inc. and contributed to Maxim magazine back when lad mags were a thing. He's also written for Esquire magazine's Dubious Achievements Awards.
In his current role at Kiplinger, Dan writes about markets and macroeconomics.
Dan holds a bachelor's degree from Oberlin College and a master's degree from Columbia University.
Disclosure: Dan does not trade individual stocks or securities. He is eternally long the U.S equity market, primarily through tax-advantaged accounts.
-
RMD, Roth, and SS: Test Your Knowledge on Retirement Tax Rules
Quiz Don't let the IRS catch you off guard. Take our quiz to reveal common retirement tax rules that could save (or cost) you thousands.
-
Nissan Recalls Over 173,000 Vehicles Over Fuel-Pump Fuse Risk
Nissan is recalling more than 173,000 U.S. vehicles due to a fuel-pump fuse short-circuit risk. Learn which models are affected and what owners need to do.
-
I Bought Palantir When It Was Trading at $8. Now It's $180 and I've Made $1 Million. What Do I Do?
What do you do with all that appreciated Palantir stock? We asked a financial expert for advice.
-
Treat Home Equity Like Other Investments in Your Retirement Plan: Look at Its Track Record
Homeowners who are considering using home equity in their retirement plan can analyze it like they do their other investments. Here's how.
-
Why Does It Take Insurers So Darn Long to Pay Claims? An Insurance Expert Explains
The process of verification, investigation and cost assessment after a loss is complex and goes beyond simply cutting a check.
-
Two Reasons to Consider Deferred Compensation in the Wake of the OBBB, From a Financial Planner
Deferred compensation plans let you potentially lower your current taxes and help to keep you out of a higher tax bracket. It's important to consider the risks.
-
Dow Sinks 301 Points on Trade War Talk: Stock Market Today
The contentious relationship between the world's two biggest economies continues to drive global financial markets.
-
The Best Gold Mutual Funds to Buy Right Now — And When to Choose An ETF Instead
Gold mutual funds offer investors exposure to the yellow precious metal, which has been red-hot this year. But a caveat is required.
-
Financial Fact vs Fiction: The Truth About Social Security Entitlement (and Reverse Mortgages' Bad Rap)
Despite the 'entitlement' moniker, Social Security and Medicare are both benefits that workers earn. And reverse mortgages can be a strategic tool for certain people. Plus, we're setting the record straight on three other myths.
-
The End of 2%? An Investment Adviser's Case for Why the Fed Should Raise Its Inflation Target
Yes, inflation can be tough on those living on fixed incomes, but protecting us from it too strictly could do our overall economy more harm than good.